Lumakras 120 mg

Lumakras 120 mg tablets contain the active ingredient sotorasib, a medication used to manage certain types of cancer. This oral treatment is manufactured by Amgen Canada Inc. and is designed for specific therapeutic uses.

Lumakras 120 mg tablets are primarily used in the management of certain cancers. Sotorasib, the active ingredient, is indicated for specific types of cancer treatment. Patients should consult their healthcare provider to determine if this medication is suitable for their condition.

Common effects of Lumakras 120 mg tablets may include gastrointestinal issues, fatigue, and changes in blood cell counts. Individual responses to sotorasib can vary, and not everyone will experience these effects. Always follow the advice of a healthcare professional regarding any concerns about side effects.

Lumakras 120 mg tablets should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients with certain medical conditions or allergies should inform their doctor before starting this medication.

Lumakras 120 mg tablets may interact with other medications, including certain antibiotics, antifungals, and other cancer treatments. Always inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances may also affect the efficacy of sotorasib.